department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Nayzilam · pharmadog

pharmadog
drugs
Nayzilam

drug

patient view →

midazolam

Marketedupdated 2mo ago

by UCB SA

Approved

community read0 votes

indications

investigational

Epilepsy

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Nayzilam

generic

midazolam [INN]

indication

Seizures

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 18, 2028

~1.5 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (6)

Jun 20, 2038formulationUS 10966990
Jun 20, 2038formulationUS 10966990
Jan 18, 2028formulationUS 82170331.5y
Jan 18, 2028formulationUS 88093221.5y
Jan 18, 2028formulationUS 92894321.5y
Jan 18, 2028formulationUS 96874951.5y

FDA exclusivities (1)

May 17, 2026ODE-243Orphan Drug (7y)

🐶 often sniffed alongside

top 2

tagDrug Shortage2 co-mentions · 2 sources
drugmidazolam hydrochloride2 co-mentions · 2 sources

Trials studying midazolam

phase2An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Canceractive not recruitingn=239
phase3A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorderrecruitingn=258
phase3A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapyactive not recruitingn=420
phase1A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participantsrecruitingn=16
phase1A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxinrecruitingn=60
phase1A Phase 1, First-in-human Study of VX-433recruitingn=118
—A Survey of Midazolam in People With Status Epilepticusrecruitingn=50
phase1A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.recruitingn=267

more trials →